225 related articles for article (PubMed ID: 34058339)
1. Interference between copper transport systems and platinum drugs.
Arnesano F; Natile G
Semin Cancer Biol; 2021 Nov; 76():173-188. PubMed ID: 34058339
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs.
Lasorsa A; Nardella MI; Rosato A; Mirabelli V; Caliandro R; Caliandro R; Natile G; Arnesano F
J Am Chem Soc; 2019 Jul; 141(30):12109-12120. PubMed ID: 31283225
[TBL] [Abstract][Full Text] [Related]
3. Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs.
Petruzzelli R; Polishchuk RS
Cells; 2019 Sep; 8(9):. PubMed ID: 31540259
[TBL] [Abstract][Full Text] [Related]
4. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
5. Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin.
Lasorsa A; Natile G; Rosato A; Tadini-Buoninsegni F; Arnesano F
Curr Med Chem; 2018 Feb; 25(4):462-477. PubMed ID: 29121854
[TBL] [Abstract][Full Text] [Related]
6. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
7. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione.
Nardella MI; Rosato A; Belviso BD; Caliandro R; Natile G; Arnesano F
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500118
[TBL] [Abstract][Full Text] [Related]
11. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
12. Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification.
Dolgova NV; Nokhrin S; Yu CH; George GN; Dmitriev OY
Biochem J; 2013 Aug; 454(1):147-56. PubMed ID: 23751120
[TBL] [Abstract][Full Text] [Related]
13. Platination of the copper transporter ATP7A involved in anticancer drug resistance.
Calandrini V; Arnesano F; Galliani A; Nguyen TH; Ippoliti E; Carloni P; Natile G
Dalton Trans; 2014 Aug; 43(31):12085-94. PubMed ID: 24983998
[TBL] [Abstract][Full Text] [Related]
14. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
Safaei R; Maktabi MH; Blair BG; Larson CA; Howell SB
J Inorg Biochem; 2009 Mar; 103(3):333-41. PubMed ID: 19124158
[TBL] [Abstract][Full Text] [Related]
15. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
16. Copper binding modulates the platination of human copper chaperone Atox1 by antitumor trans-platinum complexes.
Xi Z; Guo W; Tian C; Wang F; Liu Y
Metallomics; 2014 Mar; 6(3):491-7. PubMed ID: 24469739
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
18. Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking.
Palm-Espling ME; Andersson CD; Björn E; Linusson A; Wittung-Stafshede P
PLoS One; 2013; 8(7):e70473. PubMed ID: 23936210
[TBL] [Abstract][Full Text] [Related]
19. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
20. Copper transport systems are involved in multidrug resistance and drug transport.
Furukawa T; Komatsu M; Ikeda R; Tsujikawa K; Akiyama S
Curr Med Chem; 2008; 15(30):3268-78. PubMed ID: 19075668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
